Companies › Convergent Therapeutics
1 active drug program in 2 registered trials: 2 Phase 2; Oncology; next expected readout Aug 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Ac-225 rosopatamab tetraxetan PSMA-directed radioantibody conjugated to Ac-225 | FOLH1 | Phase 2 | PSMA PET-Positive Castration-Resistant Prostate Cancer | Aug 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06549465 | Ac-225 rosopatamab tetraxetan | Phase 2 | PSMA PET-Positive Castration-Resistant Prostate Cancer | Oncology | Aug 2027 |
| NCT06549465 | Ac-225 rosopatamab tetraxetan | Phase 2 | PSMA PET-Positive Castration-Resistant Prostate Cancer | Oncology | Aug 2027 |
CrystalGenomics Partner Therapeutics STCube Ambrx I-Mab Biopharma US
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.